Craniofacial fractures can result in a complication known as Post-traumatic
trigeminal neuropathy (PTTN). The symptoms associated with this condition
include neuropathic pain and sensory loss. The treatment of PTTN has been
dominated by microsurgical interventions and pharmacotherapy. However, these
methods are characterized by relatively low effectiveness and rarely restore
complete sensation or pain relief. PTTN is related to two distinct pathologies, which
are structural nerve damage and aberrant pain processing within the central
nervous system. Mesenchymal stem cell therapies enhence healing processes by
stimulating axonal growth, remyelination, and inflammation reduction. Biomaterial
nerve conductors not only provide structural support, but they also deliver of
growth factors and cells, which influence on nerve repair optimalisation. Physical
modalities (e.g., low-energy laser therapy) have been demonstrated to accelerate
regeneration and reduce inflammation. Neuromodulatory techniques are also
crucial in treating refractory neuropathic pain, as they act on central pain pathways.
Approaches such as peripheral nerve stimulation, repetitive transcranial magnetic
stimulation, and percutaneous trigeminal nerve stimulation improve quality of life
(when medication alone is insufficient). The future of PTTN treatment lies in a
multimodal approach combining early surgery with neuromodulation therapies.
These complex strategies aim to achieve nerve reconstruction, lasting pain relief,
and full reintegration into daily life after facial trauma.
Keywords: Trigeminal Neuropathy, Trauma, Maxillofacial Surgery,
Neuroregeneration